parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
Published 4 years ago • 244 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:16
parp inhibitors improve outcomes, qol in breast cancer
-
1:58
discussing targeted treatment with parp inhibitors for brca-mutant patients across tumor types
-
1:21
rucaparib may improve pfs in patients with ovarian cancer
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
4:14
parp inhibition in ovarian cancer: what’s next?
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
1:12
data demonstrate efficacy of 3 parp inhibitors in ovarian cancer
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
3:23
niraparib significantly improves outcomes for ovarian cancer patients
-
1:32:38
managed care implications of the expanding role of parp inhibitors in oncology
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
5:40
parp inhibitor combo shows early promise for patients with and without brca mutations
-
6:52
case 3: benefit of parp inhibitor maintenance in ovarian cancer
-
7:34
parp inhibition’s role in recurrent ovarian cancer
-
31:13
parp inhibitors and immunotherapy - dr yvette drew
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
39:03
the therapeutic potential of novel parp inhibitors in the clinic for epithelial ovarian cancer
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
4:23
comment: parp inhibitor olaparib plus bevacizumab in women with ovarian cancer